REDWOOD CITY, Calif.,
Feb. 24, 2014 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that it will release fourth quarter 2013
financial results after market close on Monday, March 3, 2014. AcelRx management
will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (877) 870-4263 for domestic callers, (855) 669-9657
for Canadian callers or (412) 317-0790 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of acute and breakthrough pain. AcelRx's
lead product candidate, Zalviso™, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following
surgery because of the side effects of morphine, the invasive IV
route of delivery and the complexity of infusion pumps.
AcelRx has announced positive results from each of the three Phase
3 clinical trials for Zalviso and has submitted an NDA to the FDA
seeking its approval. AcelRx has also announced positive
top-line results for a Phase 2 trial for ARX-04, a sufentanil
formulation for the treatment of moderate-to-severe acute pain,
funded through a grant from the U.S. Army Medical Research and
Materiel Command. The company has two additional pain
treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com.
Forward Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to anticipated approval of the NDA by the FDA
and the therapeutic potential of AcelRx Pharmaceuticals' product
candidates, including Zalviso. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
AcelRx Pharmaceuticals' ability to receive regulatory approval for
Zalviso, that fact that FDA may dispute or interpret differently
clinical results obtained to date; any delays or inability to
obtain and maintain regulatory approval of its product candidates,
including Zalviso, in the United
States and Europe; its
ability to attract additional funding partners or collaborators
with development, regulatory and commercialization expertise;
the market potential for its product candidates; and other
risks detailed in the "Risk Factors" and elsewhere in AcelRx
Pharmaceuticals' U.S. Securities and Exchange Commission filings
and reports, including its Quarterly Report on Form 10-Q filed with
the SEC on November 5, 2013.
AcelRx Pharmaceuticals undertakes no duty or obligation to
update any forward-looking statements contained in this release as
a result of new information, future events or changes in its
expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.